PCSK9 inhibitor

Phase 3Small molecule

YYun Dai Chen

PCSK9 inhibitor is one of 190 small molecule programs targeting Stroke. It is currently in Phase 3.

Indications

Total Trials

Active Trials

189

Competitors

Pipeline

Status by Indication[3][1]

Indication

StrokeActive, not recruiting

Acute Myocardial InfarctionActive, not recruiting

AtherosclerosisActive, not recruiting

Coronary Artery BypassActive, not recruiting

PCSK9 InhibitorNot yet recruiting

Optical Coherence TomographyRecruiting

Symptomatic Intracranial Atherosclerotic StenosisRecruiting

Ischemic StrokeRecruiting

StrokePreclinical

Active, not recruiting

Acute Myocardial InfarctionPreclinical

Active, not recruiting

AtherosclerosisPreclinical

Active, not recruiting

Coronary Artery BypassPreclinical

Active, not recruiting

PCSK9 InhibitorPhase 3

Not yet recruiting

Optical Coherence TomographyPhase 3

Recruiting

Symptomatic Intracranial Atherosclerotic StenosisPreclinical

Recruiting

Ischemic StrokePhase 3

Recruiting

Competition

Competitive Landscape

147 competitors in Stroke

#DrugCompanyPhaseTrials

PCSK9 inhibitor

YYun Dai Chen

Phase 3

20 2

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Phase 3

2 3

Zometa

Pfizer

Preclinical

1 4

Savella

AbbVie

Preclinical

1 5

Proamatine

Repatha

Zantac 150

1 8

Periactin

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 9

Alka-Seltzer

AAbbott

Preclinical

1 10

Haldol

DDePuy Orthopaedics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalRecruiting

Ischemic Stroke

NCT03753555

Post-ApprovalRecruiting

Optical Coherence Tomography

NCT06520904

N/ANot yet recruiting

Coronary Artery Bypass

NCT06730802

N/ANot yet recruiting

Acute Myocardial Infarction

NCT06854523

Q4 2027

Phase 2/3Not yet recruiting

Ischemic Stroke

NCT07174375

Recruiting

Acute Coronary Syndrome

NCT06738758

Clinical

Trials by Indication[1]

Acute Coronary Syndrome3 trials

Multicenter Real-World Cohort Study Evaluating the Impact of Early Intensive Lipid-Lowering Therapy on the Prognosis of Acute Coronary Syndrome Patients(ELITE-ACS)

Recruiting·YYun Dai Chen··NCT06738758·6,000 enrolled

Low-dose PCSK9 Inhibitor Combined With Stains on Serum Lipids in Chinese Population With Acute Coronary Syndrome

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 4·NCT05298475·100 enrolled

PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in Acute Coronary Syndromes (REPRESS)

Not yet recruiting·WWest China Hospital·N/A·NCT06791031·212 enrolled

Ischemic stroke3 trials

PCSK9 Inhibitors in Acute Ischemic Stroke Patients Undergoing Endovascular Therapy

Not yet recruiting·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT07174375·478 enrolled

The Effect of InTensive Statin in Ischemic Stroke With inTracranial Atherosclerotic Plaques

Recruiting·GGeneral Hospital of Shenyang Military Region·Phase 4·NCT03753555·100 enrolled

Optimal Target Low-density Lipoprotein Cholesterol Level for Small Vessel Occlusion Stroke (SVO70)

Recruiting·SSeoul National University Hospital·Preclinical·NCT06649240·4,016 enrolled

PCSK9 Inhibitor2 trials

Single Dose PCSK9 Inhibitor to Improve Cardiovascular Outcomes After PCI: A Pilot Study

Not yet recruiting·HHanyang University Seoul Hospital·Phase 4·NCT07084259·352 enrolled

Exploratory Research of PCSK9 Inhibitor on Patency of aAVF After PTA With PCB

Unknown status·RRenJi Hospital·N/A·NCT06034691·40 enrolled

Acute Myocardial Infarction2 trials

Acute Myocardial Infarction and Unstable Angina Patients With PCSK9 Inhibitor Usage Study

Unknown status·SShenzhen People's Hospital·N/A·NCT04730648·100 enrolled

Assessing Coronary Non-Culprit Plaque Early with Start of PCSK9 Inhibitors in Acute Myocardial Infarction (ACCESS-AMI)

Not yet recruiting·YYun Dai Chen·N/A·NCT06854523·300 enrolled

Optical Coherence Tomography1 trial

Effect of PCSK9 Inhibitors on Coronary Atherosclerotic Plaques Derived From Optical Coherence Tomography

Recruiting·—·Phase 4·NCT06520904·396 enrolled

9 more indications

Liver Transplant1 trial

Efficacy and Safety of Pitavastatin and PCSK9 Inhibitors in Liver Transplant Patients

Active, not recruiting·UUnknown Sponsor·Phase 4·NCT05537948·59 enrolled

Atherosclerosis1 trial

Study of Predictive Factors Related to Prognosis of Patients With Ischemic Stroke Due to Large-artery Atherosclerosis

Recruiting·TTongji Hospital··NCT04847752·1,000 enrolled

Cognitive Function1 trial

Study to Evaluate Changes in Cognitive Function in Patients Treated With PCSK9 Inhibitors

Completed·JJose Seijas Amigo··NCT04319081·180 enrolled

Aortic Stenosis1 trial

PCSK9 Inhibitors in the Progression of Aortic Stenosis

Unknown status·SSeoul National University Hospital·Phase 2·NCT03051360·140 enrolled

High Cardiovascular Risk1 trial

Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry

Completed·GGWT-TUD GmbH··NCT03110432·1,695 enrolled

Chronic Total Occlusion1 trial

Effect of Evolocumab on Chronic Total Occlusions (EVOLO-CTO)

Unknown status·LLin Zhao·Phase 4·NCT05623995·200 enrolled

Coronary Artery Bypass1 trial

Protective Effect of PCSK9 Inhibitor Against Negative Inflammatory Response and Organ Dysfunction After Coronary Artery Bypass Grafting (PANDA VIII)

Not yet recruiting·NNanjing Medical University·N/A·NCT06730802·400 enrolled

Symptomatic Intracranial Atherosclerotic Stenosis1 trial

Improving Blood Lipid Management in Symptomatic Intracranial Atherosclerotic Stenosis on Clinical Outcome

Recruiting·NNanjing First Hospital, Nanjing Medical University·N/A·NCT05397405·180 enrolled

Type 2 Diabetes1 trial

CHOlesterol Lowering and Residual Risk in Type 2 Diabetes

Completed·NNYU Langone Health·Phase 4·NCT04369664·151 enrolled

Sources

References

[1]
ClinicalTrials.gov — 20 trial records for PCSK9 inhibitor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PCSK9 inhibitor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PCSK9 inhibitor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yun Dai Chen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: YYun Dai Chen

PCSK9 inhibitor

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Trials by Indication[1]

Acute Coronary Syndrome3 trials

Ischemic stroke3 trials

PCSK9 Inhibitor2 trials

Acute Myocardial Infarction2 trials

Optical Coherence Tomography1 trial

Liver Transplant1 trial

Atherosclerosis1 trial

Cognitive Function1 trial

Aortic Stenosis1 trial

High Cardiovascular Risk1 trial

Chronic Total Occlusion1 trial

Coronary Artery Bypass1 trial

Symptomatic Intracranial Atherosclerotic Stenosis1 trial

Type 2 Diabetes1 trial

References

Drug Info

Quick Facts

Related News